Products
AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$2.6/mo
Lower than 84% of peersNiche median $5.99/mo
Creators
João Augusto
No social account linked
Launched
2mo ago
2026-09-08 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    The finance app you can talk to, now fully native.

    Sep 8 · 2mo agoLaunch page

    At the time: <5K visits/mo

MCP Server & Agent Ecosystem

GitHub · MCP / Skill

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2026-06-18

KeywordMonthly volume
mcp organizze210

Traffic data: Vaneform

Pricing

Grátis
R$ 0
CDF Finance PRO
R$ 12,99/mês

Trial: Tem 30 dias grátis · Observed 2026-11-06 · Source page

Entry price $2.6/mo, Lower than 84% of peers; “Personal Finance & Budgeting” median is $5.99/mo.View pricing benchmark

Pages & changes

Tracked since 2026-09-08

Key pages

Weekly snapshots
cdf.finance/ Snapshot 2026-11-06

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does CDF Finance cost?
Grátis: R$ 0; CDF Finance PRO: R$ 12,99/mês. Observed 2026-11-06. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does CDF Finance get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is CDF Finance and what platforms does it support?
CDF Finance is catalogued under Personal Finance & Budgeting: Suas finanças, organizadas por IA. Supported platforms: Mobile App, MCP Server.

Related products in this category

Finance / Personal Finance & Budgeting

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.